Artemisia Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Satisfied Charges ₹ 7.90 M
as on 11-12-2024
- Revenue %
(FY 2022)
- Profit -73.87%
(FY 2022)
- Ebitda 60.68%
(FY 2022)
- Net Worth -411.37%
(FY 2022)
- Total Assets -0.14%
(FY 2022)
About Artemisia Lifesciences
The Corporate was formerly known as Riasmo Lifesciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹7.90 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jyoti Jaiswal and Raj Jaiswal serve as directors at the Company.
- CIN/LLPIN
U24231GJ2003PTC042151
- Company No.
042151
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2003
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Artemisia Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Jaiswal  | Managing Director | 21-Mar-2003 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jyoti Jaiswal | Whole-Time Director | 24-Aug-2013 | Current |
Financial Performance of Artemisia Lifesciences.
Artemisia Lifesciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 73.87% decrease in profit. The company's net worth observed a substantial decline by a decrease of 411.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Artemisia Lifesciences?
In 2019, Artemisia Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anabiosis Medisciences LimitedActive 20 years 6 monthsJyoti Jaiswal and Raj Jaiswal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 05 Dec 2005 | ₹6.80 M | Satisfied |
Central Bank Of India Creation Date: 08 Dec 2004 | ₹1.10 M | Satisfied |
How Many Employees Work at Artemisia Lifesciences?
Unlock and access historical data on people associated with Artemisia Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Artemisia Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Artemisia Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
